09:00 AM EDT, 05/21/2025 (MT Newswires) -- CEL-SCI ( CVM ) said Wednesday that it has completed its Breakthrough Medicine Designation application to the Saudi Food and Drug Authority for its Multikine investigational cancer medicine.

The company said it expects its prospective Saudi partner to formally submit the application to the Saudi regulator on its behalf in the coming weeks.

The company said Multikine would immediately become available for patient access and reimbursement under the regulator's Breakthrough Medicine Designation program, which typically takes 60 days for an application response.